Viewing Study NCT03552393


Ignite Creation Date: 2025-12-25 @ 1:09 AM
Ignite Modification Date: 2025-12-25 @ 11:20 PM
Study NCT ID: NCT03552393
Status: COMPLETED
Last Update Posted: 2022-03-07
First Post: 2018-04-27
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.
Sponsor:
Organization:

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count:
Enrollment Type:
Design Primary Purpose:
Design Masking:
Phases:

Phases

Phase Brief Phase Text View
None PHASE2 View
Observational Models:
Time Perspective List:
Who Masked List: